To test this, and to independently confirm the benefit of inhibiting FAP adipogenesis for dysferlinopathy, we used a drug to inhibit the adipogenic differentiation of FAPs. Here, FAP is linked to neuromuscular disease caused by qualitative or quantitative defects of dysferlin.